Next Article in Journal
Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
Next Article in Special Issue
Structure and Optimization of Checkpoint Inhibitors
Previous Article in Journal
Genetically Engineered Mouse Models for Liver Cancer
Previous Article in Special Issue
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Open AccessFeature PaperReview

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 15; https://doi.org/10.3390/cancers12010015
Received: 8 November 2019 / Revised: 13 December 2019 / Accepted: 16 December 2019 / Published: 19 December 2019
Immunotherapy is the latest innovation for the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) entered the clinical practice and are under evaluation in clinical trials. MAbs can target highly selective and specific antigens on the cell surface of MM cells causing cell death (CD38 and CS1), convey specific cytotoxic drugs (antibody-drug conjugates), remove the breaks of the immune system (programmed death 1 (PD-1) and PD-ligand 1/2 (L1/L2) axis), or boost it against myeloma cells (bi-specific mAbs and T cell engagers). Two mAbs have been approved for the treatment of MM: the anti-CD38 daratumumab for newly-diagnosed and relapsed/refractory patients and the anti-CS1 elotuzumab in the relapse setting. These compounds are under investigation in clinical trials to explore their synergy with other anti-MM regimens, both in the front-line and relapse settings. Other antibodies targeting various antigens are under evaluation. B cell maturation antigens (BCMAs), selectively expressed on plasma cells, emerged as a promising target and several compounds targeting it have been developed. Encouraging results have been reported with antibody drug conjugates (e.g., GSK2857916) and bispecific T cell engagers (BiTEs®), including AMG420, which re-directs T cell-mediated cytotoxicity against MM cells. Here, we present an overview on mAbs currently approved for the treatment of MM and promising compounds under investigation. View Full-Text
Keywords: multiple myeloma (MM); immunotherapy; monoclonal antibodies (mAbs); antibody products; B cell maturation antigens (BCMAs); bispecific T cell engagers (BiTEs®) multiple myeloma (MM); immunotherapy; monoclonal antibodies (mAbs); antibody products; B cell maturation antigens (BCMAs); bispecific T cell engagers (BiTEs®)
Show Figures

Figure 1

MDPI and ACS Style

Bonello, F.; Mina, R.; Boccadoro, M.; Gay, F. Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers 2020, 12, 15.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop